董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Reshma Kewalramani | 女 | President, Chief Executive Officer and Director | 53 | 2153.87万美元 | 4.18 | 2026-02-13 |
| Lloyd Carney | 男 | Director | 64 | 56.42万美元 | 0.63 | 2026-02-13 |
| Sangeeta M. Bhatia | 女 | Director | 57 | 55.01万美元 | 0.44 | 2026-02-13 |
| Michel Lagarde | 男 | Director | 52 | 53.85万美元 | 0.43 | 2026-02-13 |
| Alan Garber | 男 | Director | 70 | 52.19万美元 | 3.60 | 2026-02-13 |
| Nancy Thornberry | 女 | Director | 69 | 51.93万美元 | 0.32 | 2026-02-13 |
| Suketu Upadhyay | 男 | Director | 56 | 56.30万美元 | 0.51 | 2026-02-13 |
| Diana L. McKenzie | 女 | Director | 61 | 55.00万美元 | 0.86 | 2026-02-13 |
| Jennifer Schneider | 女 | Director | 51 | 49.59万美元 | 未持股 | 2026-02-13 |
| Jeffrey M. Leiden | 男 | Executive Chairman | 70 | 659.53万美元 | 16.15 | 2026-02-13 |
| Bruce I. Sachs | 男 | Director | 66 | 60.32万美元 | 8.67 | 2026-02-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Reshma Kewalramani | 女 | President, Chief Executive Officer and Director | 53 | 2153.87万美元 | 4.18 | 2026-02-13 |
| Carmen Bozic | 女 | Chief Medical Officer and Executive Vice President,Global Medicines Development and Medical Affairs | 63 | 未披露 | 未持股 | 2026-02-13 |
| Ourania Tatsis | 女 | Chief Regulatory and Quality Officer and Executive Vice President | 56 | 733.43万美元 | 3.93 | 2026-02-13 |
| Jonathan Biller | 男 | Chief Legal Officer and Executive Vice President | 62 | 未披露 | 未持股 | 2026-02-13 |
| Kristen C. Ambrose | 女 | Chief Accounting Officer and Senior Vice President | 49 | 未披露 | 未持股 | 2026-02-13 |
| E. Morrow Atkinson, III | 男 | Chief Technical Operations Officer and Executive Vice President and Head of Biopharmaceutical Science and Manufacturing Operations | 60 | 未披露 | 未持股 | 2026-02-13 |
| Duncan J. McKechnie | 男 | Chief Commercial Officer and Executive Vice President | 57 | 未披露 | 未持股 | 2026-02-13 |
| Mark Bunnage | 男 | Chief Scientific Officer and Executive Vice President | 57 | 未披露 | 未持股 | 2026-02-13 |
| Charles F. Wagner, Jr. | 男 | Chief Operating and Financial Officer and Executive Vice President | 57 | 799.94万美元 | 3.88 | 2026-02-13 |
| Amit K. Sachdev | 男 | Chief Patient and External Affairs Officer and Executive Vice President | 58 | 619.71万美元 | 未持股 | 2026-02-13 |
董事简历
中英对照 | 中文 | 英文- Reshma Kewalramani
-
Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
Reshma Kewalramani has been Chief Executive Officer (CEO") and President since April 2020 and a member of Board of Directors since February 2020. Dr. Kewalramani was Executive Vice President and Chief Medical Officer from April 2018 through April 2020. She was Senior Vice President, Late Development from February 2017 until April 2018. Dr. Kewalramani also served on the board of Ginkgo Bioworks from September 2021 to June 2024. From Augt 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President and Head of U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the indtry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachetts General Hospital and her fellowship in Nephrology at the Massachetts General Hospital and Brigham and Women's Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She is an alumna of the Harvard Biness School, having completed the General Management Program. - Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
- Reshma Kewalramani has been Chief Executive Officer (CEO") and President since April 2020 and a member of Board of Directors since February 2020. Dr. Kewalramani was Executive Vice President and Chief Medical Officer from April 2018 through April 2020. She was Senior Vice President, Late Development from February 2017 until April 2018. Dr. Kewalramani also served on the board of Ginkgo Bioworks from September 2021 to June 2024. From Augt 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President and Head of U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the indtry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachetts General Hospital and her fellowship in Nephrology at the Massachetts General Hospital and Brigham and Women's Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She is an alumna of the Harvard Biness School, having completed the General Management Program.
- Lloyd Carney
-
Lloyd Carney，从2020年10月到2023年2月，担任Carney Technology Acquisition Corp. II（一家特殊目的收购公司）的首席收购官；ChaSerg Technology Acquisition Corp.（一家技术收购公司）的首席执行官（从2018年9月到2020年3月）；Brocade Communications Systems Inc.（全球网络硬件和软件供应商）的首席执行官兼董事；Xsigo Systems（基于云的基础设施解决方案提供商，直到2012年被Oracle收购）首席执行官；Micromuse Inc.（商业和服务保证的软件解决方案提供商，从2003年到2006年被IBM收购）首席执行官兼董事长；此前在Juniper Networks， Inc., Nortel Networks Inc.和Bay Networks担任高级领导职务；自2023年5月起担任牙买加技术大使/特别投资特使；自2022年8月起担任牙买加理工大学（牙买加的一所公立大学）校长；持有温特沃斯理工学院电气工程技术理学学士学位；莱斯利学院应用商业管理理学硕士学位，温特沃斯理工学院工程荣誉博士学位，牙买加理工大学荣誉技术博士学位。
Lloyd Carney a director since June 2018, has spent more than 25 years in the technology indtry. He started at llfleet and Nortel Networks in 1997 and in 2002 he rose to become division president. In 2003, he joined Juniper Networks as Chief Operating Officer where he oversaw the engineering, product management and manufacturing divisions. Thereafter, in 2004, he was named Chief Executive Officer of Microme, an enterprise and telecom network management company. Mr. Carney led the sale of Microme to IBM for $865 million, staying at IBM for a year after the sale to ensure a smooth transition. In 2008, he became the Chief Executive Officer of Xsigo Systems, a provider of network visualization systems, which was sold to Oracle Corporation in 2012. Mr. Carney then accepted the role of Chief Executive Officer and director of Brocade Communications Systems, Inc., a networking solutions company, in early 2013. His tenure culminated in the sale of Brocade to Broadcom Ltd. for $5.5 billion in late 2017. Mr. Carney is currently a member of the board of directors and chairs the audit committee of Visa, a leading credit card company. He is also a member of the board of directors of Vertex Pharmaceuticals, a biotechnology company. From 2018 to 2021, he served as the chairman of Nuance Communications, a leading conversational AI solution provider. From 2005 to 2014, he was a member of the board of Cypress Semiconductor Corporation, where he served on the audit and compensation committees. He was also a member of the board of Technicolor (SA), a technology company in the media and entertainment sector from 2010 until 2015, where he chaired its technology committee. In addition, since 2007 he has served as Chief Executive Officer of Carney Global Ventures, LLC, a global investment vehicle. Mr. Carney holds a B.S. degree in Electrical Engineering Technology from ntworth Institute of Technology, as ll as a M.S. degree in Applied Biness Management from Lesley College. - Lloyd Carney，从2020年10月到2023年2月，担任Carney Technology Acquisition Corp. II（一家特殊目的收购公司）的首席收购官；ChaSerg Technology Acquisition Corp.（一家技术收购公司）的首席执行官（从2018年9月到2020年3月）；Brocade Communications Systems Inc.（全球网络硬件和软件供应商）的首席执行官兼董事；Xsigo Systems（基于云的基础设施解决方案提供商，直到2012年被Oracle收购）首席执行官；Micromuse Inc.（商业和服务保证的软件解决方案提供商，从2003年到2006年被IBM收购）首席执行官兼董事长；此前在Juniper Networks， Inc., Nortel Networks Inc.和Bay Networks担任高级领导职务；自2023年5月起担任牙买加技术大使/特别投资特使；自2022年8月起担任牙买加理工大学（牙买加的一所公立大学）校长；持有温特沃斯理工学院电气工程技术理学学士学位；莱斯利学院应用商业管理理学硕士学位，温特沃斯理工学院工程荣誉博士学位，牙买加理工大学荣誉技术博士学位。
- Lloyd Carney a director since June 2018, has spent more than 25 years in the technology indtry. He started at llfleet and Nortel Networks in 1997 and in 2002 he rose to become division president. In 2003, he joined Juniper Networks as Chief Operating Officer where he oversaw the engineering, product management and manufacturing divisions. Thereafter, in 2004, he was named Chief Executive Officer of Microme, an enterprise and telecom network management company. Mr. Carney led the sale of Microme to IBM for $865 million, staying at IBM for a year after the sale to ensure a smooth transition. In 2008, he became the Chief Executive Officer of Xsigo Systems, a provider of network visualization systems, which was sold to Oracle Corporation in 2012. Mr. Carney then accepted the role of Chief Executive Officer and director of Brocade Communications Systems, Inc., a networking solutions company, in early 2013. His tenure culminated in the sale of Brocade to Broadcom Ltd. for $5.5 billion in late 2017. Mr. Carney is currently a member of the board of directors and chairs the audit committee of Visa, a leading credit card company. He is also a member of the board of directors of Vertex Pharmaceuticals, a biotechnology company. From 2018 to 2021, he served as the chairman of Nuance Communications, a leading conversational AI solution provider. From 2005 to 2014, he was a member of the board of Cypress Semiconductor Corporation, where he served on the audit and compensation committees. He was also a member of the board of Technicolor (SA), a technology company in the media and entertainment sector from 2010 until 2015, where he chaired its technology committee. In addition, since 2007 he has served as Chief Executive Officer of Carney Global Ventures, LLC, a global investment vehicle. Mr. Carney holds a B.S. degree in Electrical Engineering Technology from ntworth Institute of Technology, as ll as a M.S. degree in Applied Biness Management from Lesley College.
- Sangeeta M. Bhatia
-
Sangeeta M. Bhatia，麻省理工学院教授；约翰·J·多萝西·威尔逊，Health Sciences与技术/电气工程与计算机科学教授，自2005年起。自2020年起，成为专注于开发卫星器官作为活体治疗解决方案的私营公司Satellite Bio的联合创始人，自2018年起，成为专注于开发用于疾病监测的体内传感技术的私营公司Glympse Bio的联合创始人，1998年至2005年，担任加州大学圣迭戈分校生物工程和医学教授，Howard Hughes Medical Institute研究员，Brigham妇女医院医学系成员，博德研究所成员，科赫综合癌症研究所成员。拥有布朗大学生物医学工程学士学位，MIT机械工程学硕士和博士学位，哈佛医学院医学博士学位。
Sangeeta M. Bhatia,Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT since 2016; Investigator of the Howard Hughes Medical Institute at MIT since 2008;Co-Founder of Ropirio Therapeutics, a private biotechnology company focused on lymphatic medicine, since 2023;Co-Founder of Amplifyer Bio, a private biotechnology company focused on oncology diagnostics, since 2023;Co-Founder of Matrisome Bio, a private biotechnology company, since 2023;Co-Founder of Port Therapeutics, a private company focused on thermal bioswitches in oncology, since 2022;Co-Founder of Satellite Bio, a private company focused on developing satellite organs as living therapeutic solutions, since 2020;Co-Founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring, from 2018 until it was acquired by Sunbird Bio, Inc. in August 2023;Professor of bioengineering and medicine at the University of California at San Diego, from 1998 through 2005;Member of the Department of Medicine at Brigham and Women's Hospital and member of the Broad Institute;Holds a Sc.B. in biomedical engineering from Brown University, an S.M. and Ph.D. in Mechanical Engineering from MIT, and an M.D. from Harvard Medical School. - Sangeeta M. Bhatia，麻省理工学院教授；约翰·J·多萝西·威尔逊，Health Sciences与技术/电气工程与计算机科学教授，自2005年起。自2020年起，成为专注于开发卫星器官作为活体治疗解决方案的私营公司Satellite Bio的联合创始人，自2018年起，成为专注于开发用于疾病监测的体内传感技术的私营公司Glympse Bio的联合创始人，1998年至2005年，担任加州大学圣迭戈分校生物工程和医学教授，Howard Hughes Medical Institute研究员，Brigham妇女医院医学系成员，博德研究所成员，科赫综合癌症研究所成员。拥有布朗大学生物医学工程学士学位，MIT机械工程学硕士和博士学位，哈佛医学院医学博士学位。
- Sangeeta M. Bhatia,Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT since 2016; Investigator of the Howard Hughes Medical Institute at MIT since 2008;Co-Founder of Ropirio Therapeutics, a private biotechnology company focused on lymphatic medicine, since 2023;Co-Founder of Amplifyer Bio, a private biotechnology company focused on oncology diagnostics, since 2023;Co-Founder of Matrisome Bio, a private biotechnology company, since 2023;Co-Founder of Port Therapeutics, a private company focused on thermal bioswitches in oncology, since 2022;Co-Founder of Satellite Bio, a private company focused on developing satellite organs as living therapeutic solutions, since 2020;Co-Founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring, from 2018 until it was acquired by Sunbird Bio, Inc. in August 2023;Professor of bioengineering and medicine at the University of California at San Diego, from 1998 through 2005;Member of the Department of Medicine at Brigham and Women's Hospital and member of the Broad Institute;Holds a Sc.B. in biomedical engineering from Brown University, an S.M. and Ph.D. in Mechanical Engineering from MIT, and an M.D. from Harvard Medical School.
- Michel Lagarde
-
Michel Lagarde自2022年1月起担任Thermo Fisher Scientific Inc.（“Thermo Fisher”）的执行副总裁兼首席运营官，该公司是分析仪器、生命科学解决方案、专业诊断、实验室、制药和生物技术服务的供应商；Thermo Fisher Scientific Inc.是Vertex的供应商；Thermo Fisher Scientific Inc.的执行副总裁（2019年至2021年）；Thermo Fisher Scientific Inc.的高级副总裁兼制药服务总裁（2017年收购制药服务公司Patheon N.V。）后，Thermo Fisher Scientific Inc.于2017年加入Thermo Fisher Scientific Inc.担任高级副总裁。
Michel Lagarde Executive Vice President (2019 2021)Senior Vice President and President, Pharma Services (2017 2019)President and Chief Operating Officer, Patheon N.V. (2016 2017). - Michel Lagarde自2022年1月起担任Thermo Fisher Scientific Inc.（“Thermo Fisher”）的执行副总裁兼首席运营官，该公司是分析仪器、生命科学解决方案、专业诊断、实验室、制药和生物技术服务的供应商；Thermo Fisher Scientific Inc.是Vertex的供应商；Thermo Fisher Scientific Inc.的执行副总裁（2019年至2021年）；Thermo Fisher Scientific Inc.的高级副总裁兼制药服务总裁（2017年收购制药服务公司Patheon N.V。）后，Thermo Fisher Scientific Inc.于2017年加入Thermo Fisher Scientific Inc.担任高级副总裁。
- Michel Lagarde Executive Vice President (2019 2021)Senior Vice President and President, Pharma Services (2017 2019)President and Chief Operating Officer, Patheon N.V. (2016 2017).
- Alan Garber
-
Alan Garber，自2024年1月起担任哈佛大学临时校长；自2011年起担任哈佛大学教务长、哈佛医学院医疗保健政策Mallinckrodt教授、哈佛大学肯尼迪政府学院公共政策教授、哈佛大学陈曾熙公共卫生学院卫生政策与管理系教授；Henry J. Kaiser Jr.教授、医学教授、经济学、卫生研究和政策教授（由礼让）。他是美国国家医学院、美国临床研究学会、美国医师协会和美国艺术与科学院的成员，也是美国科学促进会、美国医师学会、现任国家经济研究局的研究助理，并担任其医疗保健计划的创始主任19年，此前曾担任美国国立卫生研究院老龄问题国家咨询委员会成员，国会预算办公室卫生顾问委员会成员。担任医疗保险和医疗补助服务中心的医疗保险证据发展和覆盖咨询委员会主席；持有哈佛大学经济学学士学位，A.M。和博士学位，以及斯坦福大学研究荣誉医学博士学位。
Alan Garber,President of Harvard University since August 2024 after serving as Interim President from January to August 2024; Provost of Harvard University and the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, Professor of Public Policy in the Harvard Kennedy School of Government, and Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health, from September 2011 to August 2024;Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University, from 1998 until 2011;Member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and the American Academy of Arts and Sciences;Member of the board of Directors of Exelixis, Inc., a genomics-based drug-discovery company, from January 2005 to May 2024;Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Royal College of Physicians;Current Research Associate with the National Bureau of Economic Research and served for nineteen years as founding Director of its Health Care Program;Previously served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office, and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services;Holds an A.B. summa cum laude, an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. with research honors from Stanford University. - Alan Garber，自2024年1月起担任哈佛大学临时校长；自2011年起担任哈佛大学教务长、哈佛医学院医疗保健政策Mallinckrodt教授、哈佛大学肯尼迪政府学院公共政策教授、哈佛大学陈曾熙公共卫生学院卫生政策与管理系教授；Henry J. Kaiser Jr.教授、医学教授、经济学、卫生研究和政策教授（由礼让）。他是美国国家医学院、美国临床研究学会、美国医师协会和美国艺术与科学院的成员，也是美国科学促进会、美国医师学会、现任国家经济研究局的研究助理，并担任其医疗保健计划的创始主任19年，此前曾担任美国国立卫生研究院老龄问题国家咨询委员会成员，国会预算办公室卫生顾问委员会成员。担任医疗保险和医疗补助服务中心的医疗保险证据发展和覆盖咨询委员会主席；持有哈佛大学经济学学士学位，A.M。和博士学位，以及斯坦福大学研究荣誉医学博士学位。
- Alan Garber,President of Harvard University since August 2024 after serving as Interim President from January to August 2024; Provost of Harvard University and the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, Professor of Public Policy in the Harvard Kennedy School of Government, and Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health, from September 2011 to August 2024;Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University, from 1998 until 2011;Member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and the American Academy of Arts and Sciences;Member of the board of Directors of Exelixis, Inc., a genomics-based drug-discovery company, from January 2005 to May 2024;Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Royal College of Physicians;Current Research Associate with the National Bureau of Economic Research and served for nineteen years as founding Director of its Health Care Program;Previously served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office, and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services;Holds an A.B. summa cum laude, an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. with research honors from Stanford University.
- Nancy Thornberry
-
Nancy Thornberry从2015年至2021年担任私人生物技术公司Kallyope, Inc.（以下简称Kallyope）的首席执行官，并继续担任该公司的董事会成员和研发主席。在加入Kallyope之前，Thornberry于2013年至2015年期间作为自由职业顾问为生物技术和制药行业的公司提供咨询服务。在此之前，她在制药公司默克（Merck & Co., Inc.）任职超过30年，担任过多个职位，最近一次是高级副总裁兼糖尿病和内分泌领域负责人。她目前担任公开生物技术公司Denali Therapeutics, Inc.和公开软件公司Schrdinger, Inc.的董事会成员。Thornberry于2013年至2020年期间担任私人生物技术研究公司Intarcia Therapeutics, Inc.的董事会成员，并于2014年至2019年担任生物技术公司Abide Therapeutics, Inc.的董事会成员，后者在2019年被H. Lundbeck A/S收购。Thornberry拥有Muhlenberg学院的化学和生物学学士学位。
Nancy Thornberry,Founder and Chief Executive Officer of Kallyope, Inc. ("Kallyope"), a private biotechnology company, from November 2015 to October 2021, and served as Chair of Research and Development through December 2023;Self-employed as a consultant to companies in the biotechnology and pharmaceutical industries from August 2013 to October 2015;Served in roles of increasing responsibility at Merck & Co., Inc., a pharmaceutical company, for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology;Holds a B.S. in Chemistry and Biology from Muhlenberg College. - Nancy Thornberry从2015年至2021年担任私人生物技术公司Kallyope, Inc.（以下简称Kallyope）的首席执行官，并继续担任该公司的董事会成员和研发主席。在加入Kallyope之前，Thornberry于2013年至2015年期间作为自由职业顾问为生物技术和制药行业的公司提供咨询服务。在此之前，她在制药公司默克（Merck & Co., Inc.）任职超过30年，担任过多个职位，最近一次是高级副总裁兼糖尿病和内分泌领域负责人。她目前担任公开生物技术公司Denali Therapeutics, Inc.和公开软件公司Schrdinger, Inc.的董事会成员。Thornberry于2013年至2020年期间担任私人生物技术研究公司Intarcia Therapeutics, Inc.的董事会成员，并于2014年至2019年担任生物技术公司Abide Therapeutics, Inc.的董事会成员，后者在2019年被H. Lundbeck A/S收购。Thornberry拥有Muhlenberg学院的化学和生物学学士学位。
- Nancy Thornberry,Founder and Chief Executive Officer of Kallyope, Inc. ("Kallyope"), a private biotechnology company, from November 2015 to October 2021, and served as Chair of Research and Development through December 2023;Self-employed as a consultant to companies in the biotechnology and pharmaceutical industries from August 2013 to October 2015;Served in roles of increasing responsibility at Merck & Co., Inc., a pharmaceutical company, for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology;Holds a B.S. in Chemistry and Biology from Muhlenberg College.
- Suketu Upadhyay
-
Suketu Upadhyay，于2023年8月被任命为首席财务官兼财务、运营和供应链执行副总裁。此前，他曾担任Zimmer Biomet Holdings， Inc.。自2019年7月加入公司以来，担任执行副总裁兼首席财务官。在加入Zimmer Biomet之前，Upadhyay先生于2016年11月至2019年6月担任Bristol-yers Squibb Company的全球金融运营高级副总裁。在加入Bristol-Myers Squibb之前，他曾担任Endo International plc的执行副总裁兼首席财务官（2013年9月至2016年11月）。在任职Endo International之前，Upadhyay先生曾担任BD的临时首席财务官、财务高级副总裁、公司财务总监和首席会计官。在担任BD的临时首席财务官和公司财务总监之前，Upadhyay先生曾担任全球财务规划和分析高级副总裁，也曾担任BD国际业务的副总裁和首席财务官。在2010年加入BD之前，Upadhyay先生在AstraZeneca PLC和Johnson & Johnson担任多个领导职务。Upadhyay先生在KPMG的公共会计部门度过了他职业生涯的早期。他还担任Vertex Pharmaceuticals Incorporated的董事会成员（2022年5月以来）。
Suketu Upadhyay was appointed Chief Financial Officer and Executive Vice President Finance, Operations and Supply Chain in Augt 2023. Previoly, he served as Executive Vice President and Chief Financial Officer since joining the Company in July 2019. Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations at Bristol Myers Squibb Company from November 2016 until June 2019. Before joining Bristol Myers Squibb, he served as Executive Vice President and Chief Financial Officer of Endo International plc from September 2013 to November 2016. Prior to his tenure at Endo International, Mr. Upadhyay served as Interim Chief Financial Officer as ll as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of BD. Prior to his role as BD's Interim Chief Financial Officer and Corporate Controller, Mr. Upadhyay was the Senior Vice President of Global Financial Planning and Analysis and also held the role of Vice President and Chief Financial Officer of BD's international biness. Before joining BD in 2010, Mr. Upadhyay held a number of leadership roles across AstraZeneca PLC and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG. He has also served as a member of the board of directors of Vertex Pharmaceuticals Incorporated since May 2022. He holds a B.S. in Finance from Albright College and an M.B.A. from the Fuqua School of Biness at Duke University. He holds the inactive designations of C.P.A. and C.M.A. - Suketu Upadhyay，于2023年8月被任命为首席财务官兼财务、运营和供应链执行副总裁。此前，他曾担任Zimmer Biomet Holdings， Inc.。自2019年7月加入公司以来，担任执行副总裁兼首席财务官。在加入Zimmer Biomet之前，Upadhyay先生于2016年11月至2019年6月担任Bristol-yers Squibb Company的全球金融运营高级副总裁。在加入Bristol-Myers Squibb之前，他曾担任Endo International plc的执行副总裁兼首席财务官（2013年9月至2016年11月）。在任职Endo International之前，Upadhyay先生曾担任BD的临时首席财务官、财务高级副总裁、公司财务总监和首席会计官。在担任BD的临时首席财务官和公司财务总监之前，Upadhyay先生曾担任全球财务规划和分析高级副总裁，也曾担任BD国际业务的副总裁和首席财务官。在2010年加入BD之前，Upadhyay先生在AstraZeneca PLC和Johnson & Johnson担任多个领导职务。Upadhyay先生在KPMG的公共会计部门度过了他职业生涯的早期。他还担任Vertex Pharmaceuticals Incorporated的董事会成员（2022年5月以来）。
- Suketu Upadhyay was appointed Chief Financial Officer and Executive Vice President Finance, Operations and Supply Chain in Augt 2023. Previoly, he served as Executive Vice President and Chief Financial Officer since joining the Company in July 2019. Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations at Bristol Myers Squibb Company from November 2016 until June 2019. Before joining Bristol Myers Squibb, he served as Executive Vice President and Chief Financial Officer of Endo International plc from September 2013 to November 2016. Prior to his tenure at Endo International, Mr. Upadhyay served as Interim Chief Financial Officer as ll as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of BD. Prior to his role as BD's Interim Chief Financial Officer and Corporate Controller, Mr. Upadhyay was the Senior Vice President of Global Financial Planning and Analysis and also held the role of Vice President and Chief Financial Officer of BD's international biness. Before joining BD in 2010, Mr. Upadhyay held a number of leadership roles across AstraZeneca PLC and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG. He has also served as a member of the board of directors of Vertex Pharmaceuticals Incorporated since May 2022. He holds a B.S. in Finance from Albright College and an M.B.A. from the Fuqua School of Biness at Duke University. He holds the inactive designations of C.P.A. and C.M.A.
- Diana L. McKenzie
-
Diana L. McKenzie,DLM Horizons, LLC（咨询有限责任公司）：顾问/所有者（2020年至今）；BrightInsight, Inc.（生物制药和医疗设备公司数字健康平台提供商）；Advisor（2020年至今）；EmPath, Inc.， Inc.（人力资本技术公司）：Advisor（2020年至2022年）；Workday, Inc.（财务和人力资本管理软件公司）：首席信息官（2016年至2019年）；安进企业技术服务和企业架构副总裁（2007 - 2010）、安进信息系统、产品开发和商业化执行董事（2004 - 2007）、礼来公司（制药公司）、礼来研究实验室集团董事。产品开发和商业化（2000年至2004年）；支持研发、企业工程、人力资源和IT架构、战略和规划的各种信息系统领导角色（1987年至1999年）；其他美国上市公司董事：Agilon Health, Inc.（2023年至今）；Vertex Pharmaceuticals Incorporated（2020年至今）；之前的美国上市公司董事（过去五年）：Change Healthcare Inc.（2019年至2022年）加州大学洛杉矶分校信息技术管理专业。
Diana L. McKenzie,Chief Information Officer of Workday, Inc., a cloud-based financial and human capital management software company, from 2016 until April 2019;Held roles of increasing responsibility at Amgen Inc., a biotechnology company, for 12 years, most recently serving as Senior Vice President and Chief Information Officer;Held various leadership roles at Eli Lilly and Company, a pharmaceutical company, for 17 years, focused on drug development, reducing time to market and improving technology and security standards;Member of the board of directors of Change Healthcare, Inc., a publicly traded healthcare technology company, from August 2019 until it was acquired by United Health Group in October 2022;Holds a Bachelor of Science degree in Computer Information Systems from Purdue University and completed the Information Technology Management Program at University of California, Los Angeles and the CERT Certification for Cybersecurity Oversight from Carnegie Mellon's Software Engineering Institute. - Diana L. McKenzie,DLM Horizons, LLC（咨询有限责任公司）：顾问/所有者（2020年至今）；BrightInsight, Inc.（生物制药和医疗设备公司数字健康平台提供商）；Advisor（2020年至今）；EmPath, Inc.， Inc.（人力资本技术公司）：Advisor（2020年至2022年）；Workday, Inc.（财务和人力资本管理软件公司）：首席信息官（2016年至2019年）；安进企业技术服务和企业架构副总裁（2007 - 2010）、安进信息系统、产品开发和商业化执行董事（2004 - 2007）、礼来公司（制药公司）、礼来研究实验室集团董事。产品开发和商业化（2000年至2004年）；支持研发、企业工程、人力资源和IT架构、战略和规划的各种信息系统领导角色（1987年至1999年）；其他美国上市公司董事：Agilon Health, Inc.（2023年至今）；Vertex Pharmaceuticals Incorporated（2020年至今）；之前的美国上市公司董事（过去五年）：Change Healthcare Inc.（2019年至2022年）加州大学洛杉矶分校信息技术管理专业。
- Diana L. McKenzie,Chief Information Officer of Workday, Inc., a cloud-based financial and human capital management software company, from 2016 until April 2019;Held roles of increasing responsibility at Amgen Inc., a biotechnology company, for 12 years, most recently serving as Senior Vice President and Chief Information Officer;Held various leadership roles at Eli Lilly and Company, a pharmaceutical company, for 17 years, focused on drug development, reducing time to market and improving technology and security standards;Member of the board of directors of Change Healthcare, Inc., a publicly traded healthcare technology company, from August 2019 until it was acquired by United Health Group in October 2022;Holds a Bachelor of Science degree in Computer Information Systems from Purdue University and completed the Information Technology Management Program at University of California, Los Angeles and the CERT Certification for Cybersecurity Oversight from Carnegie Mellon's Software Engineering Institute.
- Jennifer Schneider
-
Jennifer Schneider，自2018年起担任Livongo总裁，负责产品、数据科学、工程、市场营销、临床运营和增长战略。Schneider博士着有《解码健康信号：硅谷面向健康新时代的消费者至上方法》一书，该书为当今行业面临的慢性病问题的深度提供了指南，并探讨了企业如何利用大数据分析和人工智能为患有慢性病的人重塑护理服务。Schneider博士最近入选了Modern Healthcare的顶级临床高管名单。在加入Livongo之前，Schneider博士曾于2010年至2015年在Castlight Health担任多个关键领导职务，最近一次担任首席医疗官。Schneider博士还曾在2005年至2006年期间担任斯坦福大学健康结果研究人员和首席住院医师的领导职务，她曾在斯坦福大学、VA Palo Alto医疗保健系统和Kaiser Permanente担任主治医师。Schneider博士拥有圣十字学院本科学位-1997年约翰霍普金斯医学院医学博士学位-2002年和斯坦福大学健康服务研究理学硕士学位-2010年Schneider博士完成了她在斯坦福大学医院的内科住院医师实习。
Jennifer Schneider, Director, has been the President of Livongo since 2018 where she is responsible for product, data science, engineering, marketing, clinical operations, and growth strategy. Dr. Schneider previously served as the company's Chief Medical Officer from 2015 to 2018 where she led the company's strategic clinical product vision, data science, clinical trials, and the organization's certified diabetes educators and coaches. Dr. Schneider is the author of Decoding Health Signals: Silicon Valley's Consumer-First Approach to a New Era of Health, which offers a guide to the depth of the chronic conditions problem facing the industry today and explores how companies are using big data analytics and artificial intelligence to reinvent care delivery for people with chronic conditions. Dr. Schneider was recently named to Modern Healthcare's List of Top Clinical Executives.Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health from 2010 to 2015 most recently as Chief Medical Officer. Dr. Schneider also has held leadership roles as a health outcomes researcher and Chief Resident at Stanford University from 2005 to 2006 and she has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross -1997 a Doctor of Medicine degree from Johns Hopkins School of Medicine -2002 and a Master of Science degree in Health Services Research from Stanford University -2010 Dr. Schneider completed her internal medicine residency at Stanford University Hospital. - Jennifer Schneider，自2018年起担任Livongo总裁，负责产品、数据科学、工程、市场营销、临床运营和增长战略。Schneider博士着有《解码健康信号：硅谷面向健康新时代的消费者至上方法》一书，该书为当今行业面临的慢性病问题的深度提供了指南，并探讨了企业如何利用大数据分析和人工智能为患有慢性病的人重塑护理服务。Schneider博士最近入选了Modern Healthcare的顶级临床高管名单。在加入Livongo之前，Schneider博士曾于2010年至2015年在Castlight Health担任多个关键领导职务，最近一次担任首席医疗官。Schneider博士还曾在2005年至2006年期间担任斯坦福大学健康结果研究人员和首席住院医师的领导职务，她曾在斯坦福大学、VA Palo Alto医疗保健系统和Kaiser Permanente担任主治医师。Schneider博士拥有圣十字学院本科学位-1997年约翰霍普金斯医学院医学博士学位-2002年和斯坦福大学健康服务研究理学硕士学位-2010年Schneider博士完成了她在斯坦福大学医院的内科住院医师实习。
- Jennifer Schneider, Director, has been the President of Livongo since 2018 where she is responsible for product, data science, engineering, marketing, clinical operations, and growth strategy. Dr. Schneider previously served as the company's Chief Medical Officer from 2015 to 2018 where she led the company's strategic clinical product vision, data science, clinical trials, and the organization's certified diabetes educators and coaches. Dr. Schneider is the author of Decoding Health Signals: Silicon Valley's Consumer-First Approach to a New Era of Health, which offers a guide to the depth of the chronic conditions problem facing the industry today and explores how companies are using big data analytics and artificial intelligence to reinvent care delivery for people with chronic conditions. Dr. Schneider was recently named to Modern Healthcare's List of Top Clinical Executives.Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health from 2010 to 2015 most recently as Chief Medical Officer. Dr. Schneider also has held leadership roles as a health outcomes researcher and Chief Resident at Stanford University from 2005 to 2006 and she has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross -1997 a Doctor of Medicine degree from Johns Hopkins School of Medicine -2002 and a Master of Science degree in Health Services Research from Stanford University -2010 Dr. Schneider completed her internal medicine residency at Stanford University Hospital.
- Jeffrey M. Leiden
-
Jeffrey M. Leiden是执行主席，他于2020年4月起担任该职位。2012年至2020年3月，他担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁。2009年7月至今担任Vertex Pharmaceuticals Incorporated董事会成员，2012年5月至今担任Vertex Pharmaceuticals Incorporated董事会主席，并于2010年10月至2011年12月担任Vertex Pharmaceuticals Incorporated首席独立董事。Leiden博士于2006年至2012年1月期间担任生命科学风险投资公司Clarus风险投资公司的董事总经理。Leiden博士曾于2001年至2006年担任Pharmaceuticals Products Group 雅培的总裁兼首席运营官，并且是雅培的董事会成员。从1987年到2000年，Leiden博士担任过多个学术职务，包括芝加哥大学罗森医学和病理学教授和心脏病学主任兼心血管研究所所长、哈佛大学公共卫生学院Elkan R. Blout生物科学教授和哈佛医学院医学教授。他是美国艺术与科学院和美国国家科学院医学研究所的当选成员。Leiden博士自2015年起担任私营保险公司马萨诸塞州共同人寿保险公司的董事会成员。Leiden博士自2022年起担任私营生物技术公司Odyssey Therapeutics的董事会执行主席，并自2021年起担任私营医疗保健技术公司Casana的董事会主席。Leiden博士曾于2006年至2012年1月担任Shire PLC的董事和董事会非执行副主席，于2014年12月至2019年5月担任奎斯特诊疗的董事，并于2021年4月至2022年12月担任Revolution Healthcare Acquisition Corp.的董事长。Leiden博士在芝加哥大学获得了医学博士、博士和学士学位。
Jeffrey M. Leiden is Executive Chairman, a position he has held since in April 2020. He was Chief Executive Officer and President from 2012 through March 2020. He has been a member of Board of Directors since July 2009, the Chairman of Board of Directors since May 2012, and served as lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clar Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden was a director and the non executive Vice Chairman of the board of Shire plc, from 2006 to January 2012, a director of Quest Diagnostics, from December 2014 to May 2019, and the Chairman of Revolution Healthcare Acquisition Corp., from April 2021 to December 2022. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago. - Jeffrey M. Leiden是执行主席，他于2020年4月起担任该职位。2012年至2020年3月，他担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁。2009年7月至今担任Vertex Pharmaceuticals Incorporated董事会成员，2012年5月至今担任Vertex Pharmaceuticals Incorporated董事会主席，并于2010年10月至2011年12月担任Vertex Pharmaceuticals Incorporated首席独立董事。Leiden博士于2006年至2012年1月期间担任生命科学风险投资公司Clarus风险投资公司的董事总经理。Leiden博士曾于2001年至2006年担任Pharmaceuticals Products Group 雅培的总裁兼首席运营官，并且是雅培的董事会成员。从1987年到2000年，Leiden博士担任过多个学术职务，包括芝加哥大学罗森医学和病理学教授和心脏病学主任兼心血管研究所所长、哈佛大学公共卫生学院Elkan R. Blout生物科学教授和哈佛医学院医学教授。他是美国艺术与科学院和美国国家科学院医学研究所的当选成员。Leiden博士自2015年起担任私营保险公司马萨诸塞州共同人寿保险公司的董事会成员。Leiden博士自2022年起担任私营生物技术公司Odyssey Therapeutics的董事会执行主席，并自2021年起担任私营医疗保健技术公司Casana的董事会主席。Leiden博士曾于2006年至2012年1月担任Shire PLC的董事和董事会非执行副主席，于2014年12月至2019年5月担任奎斯特诊疗的董事，并于2021年4月至2022年12月担任Revolution Healthcare Acquisition Corp.的董事长。Leiden博士在芝加哥大学获得了医学博士、博士和学士学位。
- Jeffrey M. Leiden is Executive Chairman, a position he has held since in April 2020. He was Chief Executive Officer and President from 2012 through March 2020. He has been a member of Board of Directors since July 2009, the Chairman of Board of Directors since May 2012, and served as lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clar Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden was a director and the non executive Vice Chairman of the board of Shire plc, from 2006 to January 2012, a director of Quest Diagnostics, from December 2014 to May 2019, and the Chairman of Revolution Healthcare Acquisition Corp., from April 2021 to December 2022. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
- Bruce I. Sachs
-
Bruce I. Sachs，风险投资公司Charles River Ventures（“CRV”）名誉合伙人；CRV超过20年的普通合伙人，其中担任管理合伙人超过10年；1998年至1999年担任Ascend Communications，Inc.执行副总裁兼总经理；1997年至1998年被Ascend Communications收购之前担任Stratus Computer，Inc.总裁兼首席执行官；1995年至1997年担任Bay Networks，Inc.执行副总裁兼互联网电信业务集团总经理；Xylogics总裁兼首席执行官，Inc.从1993年至1995年被Bay Networks收购；拥有巴克内尔大学电气工程学士学位、康奈尔大学电气工程硕士学位和东北大学工商管理硕士学位。
Bruce I. Sachs,Partner Emeritus at Charles River Ventures ("CRV"), a venture capital firm; General Partner at CRV for more than 20 years, including more than 10 years as the Managing Partner;Executive Vice President and General Manager of Ascend Communications, Inc. from 1998 to 1999;President and Chief Executive Officer of Stratus Computer, Inc. from 1997 until it was acquired by Ascend Communications in 1998;Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. from 1995 to 1997;President and Chief Executive Officer of Xylogics, Inc. from 1993 until it was acquired by Bay Networks in 1995;Holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University. - Bruce I. Sachs，风险投资公司Charles River Ventures（“CRV”）名誉合伙人；CRV超过20年的普通合伙人，其中担任管理合伙人超过10年；1998年至1999年担任Ascend Communications，Inc.执行副总裁兼总经理；1997年至1998年被Ascend Communications收购之前担任Stratus Computer，Inc.总裁兼首席执行官；1995年至1997年担任Bay Networks，Inc.执行副总裁兼互联网电信业务集团总经理；Xylogics总裁兼首席执行官，Inc.从1993年至1995年被Bay Networks收购；拥有巴克内尔大学电气工程学士学位、康奈尔大学电气工程硕士学位和东北大学工商管理硕士学位。
- Bruce I. Sachs,Partner Emeritus at Charles River Ventures ("CRV"), a venture capital firm; General Partner at CRV for more than 20 years, including more than 10 years as the Managing Partner;Executive Vice President and General Manager of Ascend Communications, Inc. from 1998 to 1999;President and Chief Executive Officer of Stratus Computer, Inc. from 1997 until it was acquired by Ascend Communications in 1998;Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. from 1995 to 1997;President and Chief Executive Officer of Xylogics, Inc. from 1993 until it was acquired by Bay Networks in 1995;Holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University.
高管简历
中英对照 | 中文 | 英文- Reshma Kewalramani
Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
Reshma Kewalramani has been Chief Executive Officer (CEO") and President since April 2020 and a member of Board of Directors since February 2020. Dr. Kewalramani was Executive Vice President and Chief Medical Officer from April 2018 through April 2020. She was Senior Vice President, Late Development from February 2017 until April 2018. Dr. Kewalramani also served on the board of Ginkgo Bioworks from September 2021 to June 2024. From Augt 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President and Head of U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the indtry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachetts General Hospital and her fellowship in Nephrology at the Massachetts General Hospital and Brigham and Women's Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She is an alumna of the Harvard Biness School, having completed the General Management Program.- Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
- Reshma Kewalramani has been Chief Executive Officer (CEO") and President since April 2020 and a member of Board of Directors since February 2020. Dr. Kewalramani was Executive Vice President and Chief Medical Officer from April 2018 through April 2020. She was Senior Vice President, Late Development from February 2017 until April 2018. Dr. Kewalramani also served on the board of Ginkgo Bioworks from September 2021 to June 2024. From Augt 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President and Head of U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the indtry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachetts General Hospital and her fellowship in Nephrology at the Massachetts General Hospital and Brigham and Women's Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. She is an alumna of the Harvard Biness School, having completed the General Management Program.
- Carmen Bozic
Carmen Bozic是Vertex Pharmaceuticals Incorporated全球药品开发和医疗事务执行副总裁，自2019年10月起担任该职位，自2020年4月起担任Vertex Pharmaceuticals Incorporated首席医疗官。2019年5月至2019年10月担任Vertex Pharmaceuticals Incorporated高级副总裁兼全球临床开发主管。在加入Vertex之前，Bozic博士在Biogen Inc.工作了20多年，这是一家专注于神经系统疾病的生物技术公司，最近一次是在2015年至2019年5月期间担任全球发展和产品组合转型高级副总裁，并在2013年至2015年期间担任临床和安全科学高级副总裁。Bozic博士曾担任FDA风险沟通咨询委员会的行业代表，并且是PhRMA临床和临床前开发委员会以及BioMotiv管理委员会的成员。她是Akili Interactive临床咨询委员会的成员。她获得了医学博士学位，医学硕士学位，完成了她的住院医师资格，并且是麦吉尔大学内科的首席住院医师。她在布莱根妇女医院完成了肺部和重症监护医学的研究金，在加入生物制药行业之前，她是贝斯以色列女执事医疗中心和哈佛医学院的副医师。
Carmen Bozic is Executive Vice President, Global Medicines Development and Medical Affairs, a position she has held since October 2019, and she has been Chief Medical Officer since April 2020. She was Senior Vice President and Head of Global Clinical Development from May 2019 to October 2019. Prior to joining , Dr. Bozic spent more than 20 Global Development and Portfolio Transformation from 2015 to May 2019 and as Senior Vice President of Clinical and Safety Sciences from 2013 to 2015. Dr. Bozic has served as the indtry representative to the FDA's Risk Communication Advisory Committee, and was a member of PhRMA's Clinical and Preclinical Development Committee and the Board of Managers at BioMotiv. She received her M.D., C.M., completed her residency, and was Chief Resident in Internal Medicine at McGill University. She completed her fellowship in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical indtry.- Carmen Bozic是Vertex Pharmaceuticals Incorporated全球药品开发和医疗事务执行副总裁，自2019年10月起担任该职位，自2020年4月起担任Vertex Pharmaceuticals Incorporated首席医疗官。2019年5月至2019年10月担任Vertex Pharmaceuticals Incorporated高级副总裁兼全球临床开发主管。在加入Vertex之前，Bozic博士在Biogen Inc.工作了20多年，这是一家专注于神经系统疾病的生物技术公司，最近一次是在2015年至2019年5月期间担任全球发展和产品组合转型高级副总裁，并在2013年至2015年期间担任临床和安全科学高级副总裁。Bozic博士曾担任FDA风险沟通咨询委员会的行业代表，并且是PhRMA临床和临床前开发委员会以及BioMotiv管理委员会的成员。她是Akili Interactive临床咨询委员会的成员。她获得了医学博士学位，医学硕士学位，完成了她的住院医师资格，并且是麦吉尔大学内科的首席住院医师。她在布莱根妇女医院完成了肺部和重症监护医学的研究金，在加入生物制药行业之前，她是贝斯以色列女执事医疗中心和哈佛医学院的副医师。
- Carmen Bozic is Executive Vice President, Global Medicines Development and Medical Affairs, a position she has held since October 2019, and she has been Chief Medical Officer since April 2020. She was Senior Vice President and Head of Global Clinical Development from May 2019 to October 2019. Prior to joining , Dr. Bozic spent more than 20 Global Development and Portfolio Transformation from 2015 to May 2019 and as Senior Vice President of Clinical and Safety Sciences from 2013 to 2015. Dr. Bozic has served as the indtry representative to the FDA's Risk Communication Advisory Committee, and was a member of PhRMA's Clinical and Preclinical Development Committee and the Board of Managers at BioMotiv. She received her M.D., C.M., completed her residency, and was Chief Resident in Internal Medicine at McGill University. She completed her fellowship in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical indtry.
- Ourania Tatsis
Ourania Tatsis自2020年8月起担任Vertex Pharmaceuticals Incorporated的执行副总裁、首席监管和质量官。她曾于2019年10月至2020年8月担任Vertex Pharmaceuticals Incorporated的高级副总裁兼首席监管官。2017年9月至2019年10月，她担任Vertex Pharmaceuticals Incorporated的全球监管事务高级副总裁。在加入Vertex之前，Tatsis博士在几家制药公司担任越来越重要的职务，包括赛诺菲、施泰宁、辉瑞和惠氏。最近，从2014年到2017年，她在赛诺菲基因酶业务部门担任副总裁兼全球监管事务主管，专注于炎症/免疫学、罕见疾病、多发性硬化症、眼科学、神经学和肿瘤学/免疫肿瘤学。Tatsis博士还曾在Wistar研究所担任副参谋科学家和免疫学和疫苗开发研究员，并在Thomas Jefferson大学完成了免疫学博士后研究。她在佛蒙特大学获得细胞和分子生物学博士学位，并在坦普尔大学获得生物学学士学位。
Ourania Tatsis is Executive Vice President, Chief Regulatory and Quality Officer, a position she has held since Augt Immunology and Vaccine Development at the Wistar Institute and completed a post doctoral research fellowship in Immunology at Thomas Jefferson University. Dr. Tatsis has served as a member of the board of directors at Odyssey Therapeutics since October 2025, and previoly served on the board of directors of Verve Therapeutics from June 2024 until July 2025, when it was acquired by Eli Lilly. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and holds a B.S. in Biology from Temple University.- Ourania Tatsis自2020年8月起担任Vertex Pharmaceuticals Incorporated的执行副总裁、首席监管和质量官。她曾于2019年10月至2020年8月担任Vertex Pharmaceuticals Incorporated的高级副总裁兼首席监管官。2017年9月至2019年10月，她担任Vertex Pharmaceuticals Incorporated的全球监管事务高级副总裁。在加入Vertex之前，Tatsis博士在几家制药公司担任越来越重要的职务，包括赛诺菲、施泰宁、辉瑞和惠氏。最近，从2014年到2017年，她在赛诺菲基因酶业务部门担任副总裁兼全球监管事务主管，专注于炎症/免疫学、罕见疾病、多发性硬化症、眼科学、神经学和肿瘤学/免疫肿瘤学。Tatsis博士还曾在Wistar研究所担任副参谋科学家和免疫学和疫苗开发研究员，并在Thomas Jefferson大学完成了免疫学博士后研究。她在佛蒙特大学获得细胞和分子生物学博士学位，并在坦普尔大学获得生物学学士学位。
- Ourania Tatsis is Executive Vice President, Chief Regulatory and Quality Officer, a position she has held since Augt Immunology and Vaccine Development at the Wistar Institute and completed a post doctoral research fellowship in Immunology at Thomas Jefferson University. Dr. Tatsis has served as a member of the board of directors at Odyssey Therapeutics since October 2025, and previoly served on the board of directors of Verve Therapeutics from June 2024 until July 2025, when it was acquired by Eli Lilly. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and holds a B.S. in Biology from Temple University.
- Jonathan Biller
Jonathan Biller，从2019年11月到加入Vertex Pharmaceuticals Incorporated，他曾在Agios Pharmaceuticals， Inc.担任多个执行职务，包括首席法务官，最近担任首席财务官和公司事务主管。在Agios之前，他于2018年7月至2019年11月担任Celgene的执行副总裁兼总法律顾问，负责其全球法律职能，并于2011年至2018年6月担任税务和财务高级副总裁。加入Celgene之前，他是Bunge Limited（一家全球上市的农业和食品公司）的总法律顾问、首席税务官和秘书。在职业生涯早期，他曾在爱尔康公司担任各种领导职务，并担任Hopkins & Sutter和Foley & Lardner的合伙人。他持有Brown University的学士学位和Yale Law School的法学博士学位。
Jonathan Biller has been Executive Vice President, Chief Legal Officer since September 2022. From November 2019 until he joined , Mr. Biller served in several executive roles at Agios Pharmaceuticals, Inc., including Chief Legal Officer and, most recently, Chief Financial Officer and Head of Corporate Affairs. Prior to Agios, he served as Executive Vice President, General Counsel at Celgene from July 2018 to November 2019, where he was responsible for their global legal function, and served as Senior Vice President, Tax and Treasury from 2011 to June 2018. Prior to Celgene, Mr. Biller was General Counsel, Chief Tax Officer and Secretary at Bunge Limited, a global publicly traded agriculture and food company. Earlier in his career he held vario leadership roles at Alcon, Inc. and was a partner at Hopkins & Sutter and Foley & Lardner. Mr. Biller holds a B.A. from Brown University and a J.D. from Yale Law School.- Jonathan Biller，从2019年11月到加入Vertex Pharmaceuticals Incorporated，他曾在Agios Pharmaceuticals， Inc.担任多个执行职务，包括首席法务官，最近担任首席财务官和公司事务主管。在Agios之前，他于2018年7月至2019年11月担任Celgene的执行副总裁兼总法律顾问，负责其全球法律职能，并于2011年至2018年6月担任税务和财务高级副总裁。加入Celgene之前，他是Bunge Limited（一家全球上市的农业和食品公司）的总法律顾问、首席税务官和秘书。在职业生涯早期，他曾在爱尔康公司担任各种领导职务，并担任Hopkins & Sutter和Foley & Lardner的合伙人。他持有Brown University的学士学位和Yale Law School的法学博士学位。
- Jonathan Biller has been Executive Vice President, Chief Legal Officer since September 2022. From November 2019 until he joined , Mr. Biller served in several executive roles at Agios Pharmaceuticals, Inc., including Chief Legal Officer and, most recently, Chief Financial Officer and Head of Corporate Affairs. Prior to Agios, he served as Executive Vice President, General Counsel at Celgene from July 2018 to November 2019, where he was responsible for their global legal function, and served as Senior Vice President, Tax and Treasury from 2011 to June 2018. Prior to Celgene, Mr. Biller was General Counsel, Chief Tax Officer and Secretary at Bunge Limited, a global publicly traded agriculture and food company. Earlier in his career he held vario leadership roles at Alcon, Inc. and was a partner at Hopkins & Sutter and Foley & Lardner. Mr. Biller holds a B.A. from Brown University and a J.D. from Yale Law School.
- Kristen C. Ambrose
Kristen C. Ambrose是Vertex Pharmaceuticals Incorporated高级副总裁、首席会计官，自2021年5月起担任该职位。Ambrose女士此前于2021年3月起担任Vertex Pharmaceuticals Incorporated会计、税务、财务、战略采购和企业服务高级副总裁。从2003年2月到加入Vertex，Ambrose女士在医疗设备公司Boston Scientific Corporation担任越来越重要的职务，最近于2019年7月至2021年3月担任财务副总裁兼全球内窥镜部门财务总监，并于2017年2月至2019年6月担任全球内部审计副总裁。在加入Boston Scientific Corporation之前，Ambrose女士曾在安永会计师事务所担任会计师。她在弗吉尼亚大学获得商业学士学位，是一名注册会计师。
Kristen C. Ambrose is Senior Vice President, Chief Accounting Officer, a position she has held since May 2021. Ms. Global Endoscopy Division from July 2019 to March 2021 and as Vice President of Global Internal Audit from February 2017 to June 2019. Prior to Boston Scientific Corporation, Ms. Ambrose served as an accountant at Ernst & Young LLP. She received her B.S. in Commerce from the University of Virginia and is a Certified Public Accountant.- Kristen C. Ambrose是Vertex Pharmaceuticals Incorporated高级副总裁、首席会计官，自2021年5月起担任该职位。Ambrose女士此前于2021年3月起担任Vertex Pharmaceuticals Incorporated会计、税务、财务、战略采购和企业服务高级副总裁。从2003年2月到加入Vertex，Ambrose女士在医疗设备公司Boston Scientific Corporation担任越来越重要的职务，最近于2019年7月至2021年3月担任财务副总裁兼全球内窥镜部门财务总监，并于2017年2月至2019年6月担任全球内部审计副总裁。在加入Boston Scientific Corporation之前，Ambrose女士曾在安永会计师事务所担任会计师。她在弗吉尼亚大学获得商业学士学位，是一名注册会计师。
- Kristen C. Ambrose is Senior Vice President, Chief Accounting Officer, a position she has held since May 2021. Ms. Global Endoscopy Division from July 2019 to March 2021 and as Vice President of Global Internal Audit from February 2017 to June 2019. Prior to Boston Scientific Corporation, Ms. Ambrose served as an accountant at Ernst & Young LLP. She received her B.S. in Commerce from the University of Virginia and is a Certified Public Accountant.
- E. Morrow Atkinson, III
E. Morrow Atkinson, III，自2023年8月起担任Vertex Pharmaceuticals Incorporated执行副总裁、首席技术运营官、生物制药科学和制造运营主管。此前担任Vertex Pharmaceuticals Incorporated高级副总裁，2020年7月至今担任商业制造与供应链主管。在加入Vertex Pharmaceuticals Incorporated之前，Atkinson博士曾在百时美施贵宝公司担任多个职务，包括于2019年9月至2020年6月担任全球制造运营高级副总裁；于2019年1月至2019年9月担任公司细胞治疗和全球开发与制造副总裁兼集成负责人；于2017年6月至2019年1月担任生物制品内部制造副总裁；于2012年至2017年6月担任生物制品开发和临床制造副总裁。在加入百时美施贵宝之前，他曾在Cook Pharmica，LLC（现由Catalent, Inc.所有）和89bio, Inc.担任多个职务。Atkinson博士自2022年2月起担任上市生物制药公司TERM3的董事会成员。Atkinson博士拥有印第安纳大学生物学学士学位和斯坦福大学生物科学博士学位。
E. Morrow Atkinson, III has been Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations since Augt 2023. He previoly served as Senior Vice President, Head of Commercial Manufacturing and Supply Chain since July 2020. Prior to joining , Dr. Atkinson served in vario roles at Bristol Myers Squibb Co., including as Senior Vice President, Global Manufacturing Operations from September 2019 to June 2020; Vice President and Integration Leader, Corporate Cell Therapy and Global Development and Manufacturing from January 2019 to September 2019; Vice President, Internal Manufacturing, Biologics from June 2017 to January 2019; and Vice President, Biologics Development and Clinical Manufacturing from 2012 to June 2017. Before Bristol Myers Squibb, he held vario roles at Cook Pharmica, LLC (now owned by Novo Holdings) and Eli Lilly. Dr. Atkinson served as a 23 member of the Board of Directors of 89bio, Inc. from February 2022 until October 2025, when it was acquired by Roche. Dr. Atkinson holds a B.S. in Biology from Indiana University and a Ph.D. in Biological Sciences from Stanford University.- E. Morrow Atkinson, III，自2023年8月起担任Vertex Pharmaceuticals Incorporated执行副总裁、首席技术运营官、生物制药科学和制造运营主管。此前担任Vertex Pharmaceuticals Incorporated高级副总裁，2020年7月至今担任商业制造与供应链主管。在加入Vertex Pharmaceuticals Incorporated之前，Atkinson博士曾在百时美施贵宝公司担任多个职务，包括于2019年9月至2020年6月担任全球制造运营高级副总裁；于2019年1月至2019年9月担任公司细胞治疗和全球开发与制造副总裁兼集成负责人；于2017年6月至2019年1月担任生物制品内部制造副总裁；于2012年至2017年6月担任生物制品开发和临床制造副总裁。在加入百时美施贵宝之前，他曾在Cook Pharmica，LLC（现由Catalent, Inc.所有）和89bio, Inc.担任多个职务。Atkinson博士自2022年2月起担任上市生物制药公司TERM3的董事会成员。Atkinson博士拥有印第安纳大学生物学学士学位和斯坦福大学生物科学博士学位。
- E. Morrow Atkinson, III has been Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations since Augt 2023. He previoly served as Senior Vice President, Head of Commercial Manufacturing and Supply Chain since July 2020. Prior to joining , Dr. Atkinson served in vario roles at Bristol Myers Squibb Co., including as Senior Vice President, Global Manufacturing Operations from September 2019 to June 2020; Vice President and Integration Leader, Corporate Cell Therapy and Global Development and Manufacturing from January 2019 to September 2019; Vice President, Internal Manufacturing, Biologics from June 2017 to January 2019; and Vice President, Biologics Development and Clinical Manufacturing from 2012 to June 2017. Before Bristol Myers Squibb, he held vario roles at Cook Pharmica, LLC (now owned by Novo Holdings) and Eli Lilly. Dr. Atkinson served as a 23 member of the Board of Directors of 89bio, Inc. from February 2022 until October 2025, when it was acquired by Roche. Dr. Atkinson holds a B.S. in Biology from Indiana University and a Ph.D. in Biological Sciences from Stanford University.
- Duncan J. McKechnie
Duncan J. McKechnie，他被任命为Vertex Pharmaceuticals Incorporated执行副总裁兼首席商务官，自2025年7月1日起生效。2013年6月至2018年9月，他担任Vertex Pharmaceuticals Incorporated全球营销副总裁。加入Vertex之前，他在Novartis AG担任越来越重要的职位，包括呼吸特许经营副总裁（2013年1月至2013年6月）；2012年4月至2013年4月担任副总裁兼品牌最大化和既定药物主管；2008年11月至2012年3月担任心血管营销副总裁。在Novartis之前，他曾在GlaxoSmithKline plc担任多个职位。他持有英国Plymouth大学的商业与市场营销学位。
Duncan J. McKechnie is Executive Vice President, Chief Commercial Officer, a position he has held since July 1, 2025. Mr. McKechnie previoly served as Senior Vice President, Head of North America Commercial from October 2018 to July 2025, and as Vice President of Global Marketing from June 2013 to September 2018. Prior to joining Vertex, Mr. McKechnie held positions of increasing responsibility at Novartis AG, including Vice President, Respiratory Franchise from January 2013 to June 2013; Vice President and Head Brand Maximization and Established Medicines from April 2012 to April 2013; and Vice President, Cardiovascular Marketing from November 2008 to March 2012. Before Novartis, Mr. McKechnie held vario roles at GlaxoSmithKline plc. Mr. McKechnie holds a Biness & Marketing degree from the University of Plymouth in England.- Duncan J. McKechnie，他被任命为Vertex Pharmaceuticals Incorporated执行副总裁兼首席商务官，自2025年7月1日起生效。2013年6月至2018年9月，他担任Vertex Pharmaceuticals Incorporated全球营销副总裁。加入Vertex之前，他在Novartis AG担任越来越重要的职位，包括呼吸特许经营副总裁（2013年1月至2013年6月）；2012年4月至2013年4月担任副总裁兼品牌最大化和既定药物主管；2008年11月至2012年3月担任心血管营销副总裁。在Novartis之前，他曾在GlaxoSmithKline plc担任多个职位。他持有英国Plymouth大学的商业与市场营销学位。
- Duncan J. McKechnie is Executive Vice President, Chief Commercial Officer, a position he has held since July 1, 2025. Mr. McKechnie previoly served as Senior Vice President, Head of North America Commercial from October 2018 to July 2025, and as Vice President of Global Marketing from June 2013 to September 2018. Prior to joining Vertex, Mr. McKechnie held positions of increasing responsibility at Novartis AG, including Vice President, Respiratory Franchise from January 2013 to June 2013; Vice President and Head Brand Maximization and Established Medicines from April 2012 to April 2013; and Vice President, Cardiovascular Marketing from November 2008 to March 2012. Before Novartis, Mr. McKechnie held vario roles at GlaxoSmithKline plc. Mr. McKechnie holds a Biness & Marketing degree from the University of Plymouth in England.
- Mark Bunnage
Mark Bunnage是执行副总裁兼首席科学官，自2026年2月起担任该职位。他于2024年3月至2026年1月担任高级副总裁兼全球研究主管，于2021年7月至2024年3月担任高级副总裁兼研究主管，并于2016年8月至2021年7月担任波士顿研究公司高级副总裁兼现场主管。在加入福泰制药之前，Bunnage博士在辉瑞公司有20年的职业生涯，在那里他担任的职位责任越来越大，包括Sandwich Laboratories全球药物化学副总裁和药物化学负责人。Bunnage博士是英国皇家化学学会的会员，也是英国皇家生物学会的会员。他还担任英国牛津大学化学客座教授，是英国达勒姆大学化学系战略顾问委员会成员。Bunnage博士在达勒姆大学获得化学学士学位，在牛津大学获得化学博士学位。他在加利福尼亚州拉霍亚的斯克里普斯研究所完成了作为北约研究员的博士后研究。
Mark Bunnage is Executive Vice President and Chief Scientific Officer, a position he has held since February 2026. He was Senior Vice President & Head of Global Research from March 2024 through January 2026, Senior Vice President & Head of Research from July 2021 to March 2024, and Senior Vice President & Site Head, Boston Research, from Augt 2016 to July 2021. Prior to joining Vertex, Dr. Bunnage had a 20 year career at Pfizer Inc. where he held positions of increasing responsibility, including Vice President, Worldwide Medicinal Chemistry and Head of Medicinal Chemistry, Sandwich Laboratories. Dr. Bunnage is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Biology. He also serves as a visiting professor in chemistry at the University of Oxford, United Kingdom, and is a member of the Strategic Advisory Board for the Department of Chemistry at the University of Durham, United Kingdom. Dr. Bunnage received his B.Sc in Chemistry from the University of Durham and his D.Phil in Chemistry from the University of Oxford. He completed his postdoctoral research as a NATO Fellow at The Scripps Research Institute in La Jolla, California.- Mark Bunnage是执行副总裁兼首席科学官，自2026年2月起担任该职位。他于2024年3月至2026年1月担任高级副总裁兼全球研究主管，于2021年7月至2024年3月担任高级副总裁兼研究主管，并于2016年8月至2021年7月担任波士顿研究公司高级副总裁兼现场主管。在加入福泰制药之前，Bunnage博士在辉瑞公司有20年的职业生涯，在那里他担任的职位责任越来越大，包括Sandwich Laboratories全球药物化学副总裁和药物化学负责人。Bunnage博士是英国皇家化学学会的会员，也是英国皇家生物学会的会员。他还担任英国牛津大学化学客座教授，是英国达勒姆大学化学系战略顾问委员会成员。Bunnage博士在达勒姆大学获得化学学士学位，在牛津大学获得化学博士学位。他在加利福尼亚州拉霍亚的斯克里普斯研究所完成了作为北约研究员的博士后研究。
- Mark Bunnage is Executive Vice President and Chief Scientific Officer, a position he has held since February 2026. He was Senior Vice President & Head of Global Research from March 2024 through January 2026, Senior Vice President & Head of Research from July 2021 to March 2024, and Senior Vice President & Site Head, Boston Research, from Augt 2016 to July 2021. Prior to joining Vertex, Dr. Bunnage had a 20 year career at Pfizer Inc. where he held positions of increasing responsibility, including Vice President, Worldwide Medicinal Chemistry and Head of Medicinal Chemistry, Sandwich Laboratories. Dr. Bunnage is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Biology. He also serves as a visiting professor in chemistry at the University of Oxford, United Kingdom, and is a member of the Strategic Advisory Board for the Department of Chemistry at the University of Durham, United Kingdom. Dr. Bunnage received his B.Sc in Chemistry from the University of Durham and his D.Phil in Chemistry from the University of Oxford. He completed his postdoctoral research as a NATO Fellow at The Scripps Research Institute in La Jolla, California.
- Charles F. Wagner, Jr.
Charles F. Wagner, Jr.，如先前宣布，Wagner先生已被任命为Vertex Pharmaceuticals Incorporated首席运营官，自2025年7月1日起生效。Wagner先生在此次任命后仍将担任执行副总裁兼Vertex Pharmaceuticals Incorporated首席财务官。在任职于福泰制药之前，Wagner先生于2015年6月至2019年3月担任凯雷集团投资组合公司Ortho Clinical诊断公司的首席财务官兼财务执行副总裁。在担任该职务期间，他领导了财务、会计、税务、财务、全球金融体系、贷方关系以及收购和资产剥离集团，还共同领导了几个企业范围内的项目。2012年7月至2015年6月，Wagner先生担任科学仪器制造商Bruker Corporation的执行副总裁兼首席财务官。在此之前，Wagner先生曾担任企业软件提供商Progress Software Corporation和生命科学工具市场产品和服务的全球供应商Millipore Corporation的首席财务官。Wagner先生于2014年4月至2017年8月担任Good Start Genetics，Inc.的董事，并于2010年8月至2012年6月担任Bruker Corporation的董事和审计委员会成员。他担任The TJX Companies，Inc.的董事会成员，自2023年9月起。Wagner先生拥有波士顿学院会计学学士学位和哈佛商学院工商管理硕士学位。
Charles F. Wagner, Jr. is Executive Vice President, Chief Operating & Financial Officer, a position he has held since July 2025. Mr. Wagner was Executive Vice President, Chief Financial Officer from April 2019 through June 2025. Prior to his role at Vertex, Mr. Wagner was Chief Financial Officer and Executive Vice President, Finance, of Ortho Clinical tax, treasury, global financial systems, lender relations, and acquisitions and divestiture groups. From July 2012 to June 2015, Mr. Wagner served as Executive Vice President, Chief Financial Officer of Bruker Corporation, a scientific instruments manufacturer. Prior to that, Mr. Wagner served as Chief Financial Officer for Progress Software Corporation, a provider of enterprise software, and Millipore Corporation, a global provider of products and services in the life science tools market. Mr. Wagner served as a director of Good Start Genetics, Inc., from April 2014 to Augt 2017 and served as a director and member of the Audit Committee of Bruker Corporation from Augt 2010 to June 2012. He has served as a member of the Board of Directors of The TJX Companies, Inc., since September 2023. Mr. Wagner holds a B.S. in Accounting from Boston College and a M.B.A from Harvard Biness School.- Charles F. Wagner, Jr.，如先前宣布，Wagner先生已被任命为Vertex Pharmaceuticals Incorporated首席运营官，自2025年7月1日起生效。Wagner先生在此次任命后仍将担任执行副总裁兼Vertex Pharmaceuticals Incorporated首席财务官。在任职于福泰制药之前，Wagner先生于2015年6月至2019年3月担任凯雷集团投资组合公司Ortho Clinical诊断公司的首席财务官兼财务执行副总裁。在担任该职务期间，他领导了财务、会计、税务、财务、全球金融体系、贷方关系以及收购和资产剥离集团，还共同领导了几个企业范围内的项目。2012年7月至2015年6月，Wagner先生担任科学仪器制造商Bruker Corporation的执行副总裁兼首席财务官。在此之前，Wagner先生曾担任企业软件提供商Progress Software Corporation和生命科学工具市场产品和服务的全球供应商Millipore Corporation的首席财务官。Wagner先生于2014年4月至2017年8月担任Good Start Genetics，Inc.的董事，并于2010年8月至2012年6月担任Bruker Corporation的董事和审计委员会成员。他担任The TJX Companies，Inc.的董事会成员，自2023年9月起。Wagner先生拥有波士顿学院会计学学士学位和哈佛商学院工商管理硕士学位。
- Charles F. Wagner, Jr. is Executive Vice President, Chief Operating & Financial Officer, a position he has held since July 2025. Mr. Wagner was Executive Vice President, Chief Financial Officer from April 2019 through June 2025. Prior to his role at Vertex, Mr. Wagner was Chief Financial Officer and Executive Vice President, Finance, of Ortho Clinical tax, treasury, global financial systems, lender relations, and acquisitions and divestiture groups. From July 2012 to June 2015, Mr. Wagner served as Executive Vice President, Chief Financial Officer of Bruker Corporation, a scientific instruments manufacturer. Prior to that, Mr. Wagner served as Chief Financial Officer for Progress Software Corporation, a provider of enterprise software, and Millipore Corporation, a global provider of products and services in the life science tools market. Mr. Wagner served as a director of Good Start Genetics, Inc., from April 2014 to Augt 2017 and served as a director and member of the Audit Committee of Bruker Corporation from Augt 2010 to June 2012. He has served as a member of the Board of Directors of The TJX Companies, Inc., since September 2023. Mr. Wagner holds a B.S. in Accounting from Boston College and a M.B.A from Harvard Biness School.
- Amit K. Sachdev
Amit K. Sachdev，2014年10月至今，担任Vertex Pharmaceuticals Incorporated的政策、准入及价值执行副总裁，管理Vertex Pharmaceuticals Incorporated药品及替代药品的全球市场准入、健康经济与产出研究。他于2007年加入本公司，担任高级副总裁，领导Vertex Pharmaceuticals Incorporated的政府事务、公共政策、患者宣传方案。2010-2013，他在加拿大建立了公司的第一个国际性商业业务。加入Vertex Pharmaceuticals Incorporated之前，他曾担任Biotechnology Industry Organization BIO的健康部执行副总裁，以及FDA的副主任，还在FDA担任过其它一些高级职务。加入FDA之前，他曾担任美国众议院能源与商务委员会的多数法律顾问，还先后在Chemical Manufacturers Association、律师事务所Ropes & Gray LLP从事过法律执业。他在Carnegie Mellon University获得学士学位，在Emory University School of Law获得法律博士学位。
Amit K. Sachdev is Executive Vice President, Chief Patient and External Affairs Officer, a role he has held since July 2023. From October 2019 to July 2023, he was Executive Vice President, Chief Patient Officer. In addition, Mr. Sachdev served in the role of Chief of Staff to the CEO from April 2020 to March 2023. He served as Executive Vice President and Chief Regulatory Officer from January 2017 until September 2019, and as Executive Vice President, Policy, Access and Value from October 2014 through December 2016. In 2010, he established first international commercial operations in Canada. In 2007, he joined as a Senior Vice President, to establish government affairs and public policy activities, as ll as patient advocacy programs. Prior to joining , Mr. Sachdev served as Executive Vice President, Health, of the Biotechnology Indtry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. Hoe of Representatives and practiced law at the American Chemistry Council, and subsequently at the law firm of Ropes & Gray LLP. He served as a member of the Board of Directors of Eiger BioPharmaceuticals from April 2019 to September 2024. Mr. Sachdev holds a B.S from Carnegie Mellon University and a J.D. from Emory University School of Law.- Amit K. Sachdev，2014年10月至今，担任Vertex Pharmaceuticals Incorporated的政策、准入及价值执行副总裁，管理Vertex Pharmaceuticals Incorporated药品及替代药品的全球市场准入、健康经济与产出研究。他于2007年加入本公司，担任高级副总裁，领导Vertex Pharmaceuticals Incorporated的政府事务、公共政策、患者宣传方案。2010-2013，他在加拿大建立了公司的第一个国际性商业业务。加入Vertex Pharmaceuticals Incorporated之前，他曾担任Biotechnology Industry Organization BIO的健康部执行副总裁，以及FDA的副主任，还在FDA担任过其它一些高级职务。加入FDA之前，他曾担任美国众议院能源与商务委员会的多数法律顾问，还先后在Chemical Manufacturers Association、律师事务所Ropes & Gray LLP从事过法律执业。他在Carnegie Mellon University获得学士学位，在Emory University School of Law获得法律博士学位。
- Amit K. Sachdev is Executive Vice President, Chief Patient and External Affairs Officer, a role he has held since July 2023. From October 2019 to July 2023, he was Executive Vice President, Chief Patient Officer. In addition, Mr. Sachdev served in the role of Chief of Staff to the CEO from April 2020 to March 2023. He served as Executive Vice President and Chief Regulatory Officer from January 2017 until September 2019, and as Executive Vice President, Policy, Access and Value from October 2014 through December 2016. In 2010, he established first international commercial operations in Canada. In 2007, he joined as a Senior Vice President, to establish government affairs and public policy activities, as ll as patient advocacy programs. Prior to joining , Mr. Sachdev served as Executive Vice President, Health, of the Biotechnology Indtry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. Hoe of Representatives and practiced law at the American Chemistry Council, and subsequently at the law firm of Ropes & Gray LLP. He served as a member of the Board of Directors of Eiger BioPharmaceuticals from April 2019 to September 2024. Mr. Sachdev holds a B.S from Carnegie Mellon University and a J.D. from Emory University School of Law.